- Home
- NAT vs PHAT Comparison
NAT vs PHAT Comparison
Compare NAT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAT
- PHAT
- Stock Information
- Founded
- NAT 1995
- PHAT 2018
- Country
- NAT Bermuda
- PHAT United States
- Employees
- NAT N/A
- PHAT N/A
- Industry
- NAT Marine Transportation
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- NAT Consumer Discretionary
- PHAT Health Care
- Exchange
- NAT Nasdaq
- PHAT Nasdaq
- Market Cap
- NAT 517.8M
- PHAT 465.0M
- IPO Year
- NAT 1997
- PHAT 2019
- Fundamental
- Price
- NAT $2.75
- PHAT $6.96
- Analyst Decision
- NAT Hold
- PHAT Strong Buy
- Analyst Count
- NAT 2
- PHAT 4
- Target Price
- NAT $3.75
- PHAT $23.00
- AVG Volume (30 Days)
- NAT 3.1M
- PHAT 971.9K
- Earning Date
- NAT 02-27-2025
- PHAT 03-06-2025
- Dividend Yield
- NAT 14.60%
- PHAT N/A
- EPS Growth
- NAT N/A
- PHAT N/A
- EPS
- NAT 0.30
- PHAT N/A
- Revenue
- NAT $367,467,000.00
- PHAT $26,270,000.00
- Revenue This Year
- NAT N/A
- PHAT $7,622.43
- Revenue Next Year
- NAT $11.19
- PHAT $236.87
- P/E Ratio
- NAT $9.19
- PHAT N/A
- Revenue Growth
- NAT N/A
- PHAT N/A
- 52 Week Low
- NAT $2.41
- PHAT $6.07
- 52 Week High
- NAT $4.55
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- NAT 51.06
- PHAT 37.02
- Support Level
- NAT $2.47
- PHAT $6.36
- Resistance Level
- NAT $2.61
- PHAT $7.20
- Average True Range (ATR)
- NAT 0.11
- PHAT 0.48
- MACD
- NAT 0.04
- PHAT 0.08
- Stochastic Oscillator
- NAT 55.72
- PHAT 30.48
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters pursuant to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.